Shenzhen YHLO Biotech (688575) Q4 2024 earnings summary

Executive summary

• 2024 revenue reached 1,991.68 million RMB, down 2.99% year-over-year due to a sharp decline in COVID-related business and non-recurring gains.

• Net profit attributable to shareholders was 301.67 million RMB, down 15.03% year-over-year.

• Excluding non-recurring items, net profit rose 31.16% year-over-year, driven by strong growth in core non-COVID business.

Financial highlights

• Operating profit was 307.46 million RMB, down 9.71% year-over-year.

• Basic EPS was 0.53 RMB, down 15.87% year-over-year.

• Total assets at year-end were 4,426.23 million RMB, up 16.29% from the previous year.

• Shareholders' equity increased 7.85% year-over-year to 2,760.89 million RMB.

• Net asset per share rose 7.45% to 4.84 RMB.

Outlook and guidance

• Non-COVID core business, especially chemiluminescence, is expected to continue driving growth.